Corporate Banner
Satellite Banner
Molecular & Clinical Diagnostics
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Pfizer and Samsung Medical Center Collaborate on Liver Cancer

Published: Friday, July 16, 2010
Last Updated: Friday, July 16, 2010
Bookmark and Share
Collaboration aims to conduct joint research to identify genomic mechanisms responsible for clinical outcomes in hepatocellular carcinoma.

Samsung Medical Center and Pfizer Inc. have announced that they have formed a research partnership to jointly analyze tumors from Korean patients to generate gene expression profiles and that may ultimately direct therapies and enhance clinical outcomes in the patients with liver cancer.

The two organizations held a signing ceremony at the main conference hall located on the fifth floor of Samsung Medical Center in Seoul on June 14 to commemorate the initiation of the collaboration. A research team led by top scientists at Samsung Medical Center, including Prof. Park Cheol-Guen, Prof. Im Ho-Young and Prof. Paik Soon-Myung, Director of the Cancer Research Center, will conduct research in Seoul, while Dr. Neil Gibson, Vice President of Oncology Research, will be responsible for the joint research program at Pfizer.

Pfizer expanded into the market for targeted anticancer agents with the launch of Sutent, an anticancer agent used to treat an advanced form of kidney cancer. Since then, the company has been consistently investing in research and development of innovative drug candidates and potential treatments for patients with liver cancer, a type of cancer especially prevalent in Asia, to address the growing need for an anticancer drug treating liver cancer in the Asian market in the future. Seeing the world-class clinical environment and outstanding research capabilities in Korea, the global pharmaceutical company formed a research partnership with Samsung Medical Center as part of its commitment.

"This partnership will serve as a great opportunity to combine Pfizer's know-how in drug development and Samsung Medical Center's extensive genome information and technology in the liver cancer area," said Neil Gibson, vice president of Oncology Research Unit in Pfizer Inc.

"We further plan to share the ownership of collected and analyzed data with Samsung Medical Center, contributing to advance of a variety of oncology research in Korea," Gibson said.


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,000+ scientific posters on ePosters
  • More than 4,400+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Pfizer and Strides Arcolab to Collaborate on Generic Products
Pfizer will commercialize off-patent sterile injectable and oral products in the U.S.
Thursday, January 07, 2010
Scientific News
New Blood Test for The Earlier Diagnosis of Breast Cancer Spread
Researchers at University of Westminster have confirmed that a new blood test can detect if breast cancer has spread to other parts of the body.
Genetic Approach May Lead to New Treatments for Digestive Diseases
Researchers at UMass Medical School have identified a new molecular pathway critical for maintaining the smooth muscle tone that allows the passage of materials through the digestive system.
Biomarkers for Profiling Prostate Cancer Patients
Exiqon A/S has announced the publication of validation of prognostic microRNA biomarkers for the aggressiveness of prostate cancer in independent cohorts.
World-First Blood Test For Parkinson's
La Trobe University researchers have developed a world-first diagnostic blood test which could change the lives of people with Parkinson's disease.
Parsortix Demonstrates Benefits Over Marker-Based Systems
Research published online in the International Journal of Cancer, shows the ParsortixTM System efficiently captures and harvests intact, viable circulating tumour cells (CTCs), including EpCAM-negative CTCs, to allow for broader downstream CTC analysis.
Hepatitis C Virus Testing Guidelines Miss Too Many Cases
Urban emergency departments a good place to enact universal screening for adults.
NIH Sequences Genome of a Fungus
Researchers at the Institute have sequenced genome of human, mouse and rat Pneumocystis that cause life-threatening Pneumonia in immunosuppressed hosts.
Antibiotic Resistance Mechanism Continues to Spread
A recently discovered genetic mechanism allowing bacteria to develop and transfer resistance to colistin, one of the last-resort antibiotics, has been present in many countries across the world for more than a decade, according to late-breaking data presented at ECCMID.
Promising New Method Inhibits TB-Causing Bacteria
Researchers at UQ and UC San Francisco have found a new way to inhibit the growth of the bacterium that causes tuberculosis.
Liquid Biopsy for NSCLC
'Liquid biopsy' blood test accurately detects key genetic mutations in most common form of lung cancer, study finds.
Skyscraper Banner

SELECTBIO Market Reports
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,000+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,400+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!